BIOMARIN PHARMACEUTICAL INC (BMRN) Fundamental Analysis & Valuation

NASDAQ:BMRN • US09061G1013

Current stock price

54.1 USD
-1.17 (-2.12%)
At close:
54.58 USD
+0.48 (+0.89%)
Pre-Market:

This BMRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. BMRN Profitability Analysis

1.1 Basic Checks

  • BMRN had positive earnings in the past year.
  • BMRN had a positive operating cash flow in the past year.
  • BMRN had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years BMRN had a positive operating cash flow.
BMRN Yearly Net Income VS EBIT VS OCF VS FCFBMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M

1.2 Ratios

  • With an excellent Return On Assets value of 4.59%, BMRN belongs to the best of the industry, outperforming 90.50% of the companies in the same industry.
  • BMRN has a better Return On Equity (5.73%) than 90.89% of its industry peers.
  • With an excellent Return On Invested Capital value of 9.64%, BMRN belongs to the best of the industry, outperforming 93.60% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for BMRN is significantly below the industry average of 27.73%.
  • The 3 year average ROIC (6.29%) for BMRN is below the current ROIC(9.64%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.59%
ROE 5.73%
ROIC 9.64%
ROA(3y)4.38%
ROA(5y)2.86%
ROE(3y)5.55%
ROE(5y)3.65%
ROIC(3y)6.29%
ROIC(5y)N/A
BMRN Yearly ROA, ROE, ROICBMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 -20

1.3 Margins

  • BMRN has a Profit Margin of 10.83%. This is amongst the best in the industry. BMRN outperforms 91.09% of its industry peers.
  • BMRN's Profit Margin has declined in the last couple of years.
  • BMRN has a better Operating Margin (27.06%) than 94.96% of its industry peers.
  • In the last couple of years the Operating Margin of BMRN has grown nicely.
  • With an excellent Gross Margin value of 81.43%, BMRN belongs to the best of the industry, outperforming 85.08% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BMRN has grown nicely.
Industry RankSector Rank
OM 27.06%
PM (TTM) 10.83%
GM 81.43%
OM growth 3Y106.3%
OM growth 5YN/A
PM growth 3Y17.04%
PM growth 5Y-25.17%
GM growth 3Y1.91%
GM growth 5Y2.54%
BMRN Yearly Profit, Operating, Gross MarginsBMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BMRN Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BMRN is still creating some value.
  • BMRN has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, BMRN has more shares outstanding
  • Compared to 1 year ago, BMRN has an improved debt to assets ratio.
BMRN Yearly Shares OutstandingBMRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
BMRN Yearly Total Debt VS Total AssetsBMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • BMRN has an Altman-Z score of 5.48. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
  • BMRN has a Altman-Z score of 5.48. This is in the better half of the industry: BMRN outperforms 73.26% of its industry peers.
  • The Debt to FCF ratio of BMRN is 0.83, which is an excellent value as it means it would take BMRN, only 0.83 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 0.83, BMRN belongs to the best of the industry, outperforming 94.38% of the companies in the same industry.
  • A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.10, BMRN is doing worse than 63.18% of the companies in the same industry.
  • Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.83
Altman-Z 5.48
ROIC/WACC1.08
WACC8.91%
BMRN Yearly LT Debt VS Equity VS FCFBMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 5.21 indicates that BMRN has no problem at all paying its short term obligations.
  • The Current ratio of BMRN (5.21) is comparable to the rest of the industry.
  • BMRN has a Quick Ratio of 3.50. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
  • BMRN has a Quick ratio of 3.50. This is comparable to the rest of the industry: BMRN outperforms 44.96% of its industry peers.
Industry RankSector Rank
Current Ratio 5.21
Quick Ratio 3.5
BMRN Yearly Current Assets VS Current LiabilitesBMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. BMRN Growth Analysis

3.1 Past

  • BMRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.46%.
  • BMRN shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -17.11% yearly.
  • The Revenue has grown by 12.87% in the past year. This is quite good.
  • BMRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.60% yearly.
EPS 1Y (TTM)-19.46%
EPS 3Y83.09%
EPS 5Y-17.11%
EPS Q2Q%-137.5%
Revenue 1Y (TTM)12.87%
Revenue growth 3Y15.4%
Revenue growth 5Y11.6%
Sales Q2Q%17.03%

3.2 Future

  • Based on estimates for the next years, BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 41.22% on average per year.
  • The Revenue is expected to grow by 11.79% on average over the next years. This is quite good.
EPS Next Y145.65%
EPS Next 2Y80.04%
EPS Next 3Y59.23%
EPS Next 5Y41.22%
Revenue Next Year14.32%
Revenue Next 2Y13.27%
Revenue Next 3Y11.87%
Revenue Next 5Y11.79%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BMRN Yearly Revenue VS EstimatesBMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
BMRN Yearly EPS VS EstimatesBMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

8

4. BMRN Valuation Analysis

4.1 Price/Earnings Ratio

  • BMRN is valuated quite expensively with a Price/Earnings ratio of 30.39.
  • Based on the Price/Earnings ratio, BMRN is valued cheaper than 91.86% of the companies in the same industry.
  • BMRN is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.53, which is the current average of the S&P500 Index.
  • BMRN is valuated correctly with a Price/Forward Earnings ratio of 12.37.
  • 97.48% of the companies in the same industry are more expensive than BMRN, based on the Price/Forward Earnings ratio.
  • BMRN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 37.95.
Industry RankSector Rank
PE 30.39
Fwd PE 12.37
BMRN Price Earnings VS Forward Price EarningsBMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • 96.51% of the companies in the same industry are more expensive than BMRN, based on the Enterprise Value to EBITDA ratio.
  • 96.90% of the companies in the same industry are more expensive than BMRN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 14.51
EV/EBITDA 9.66
BMRN Per share dataBMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BMRN has an outstanding profitability rating, which may justify a higher PE ratio.
  • BMRN's earnings are expected to grow with 59.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.21
PEG (5Y)N/A
EPS Next 2Y80.04%
EPS Next 3Y59.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BMRN Dividend Analysis

5.1 Amount

  • No dividends for BMRN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BMRN Fundamentals: All Metrics, Ratios and Statistics

BIOMARIN PHARMACEUTICAL INC

NASDAQ:BMRN (4/16/2026, 8:16:12 PM)

Premarket: 54.58 +0.48 (+0.89%)

54.1

-1.17 (-2.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-23
Earnings (Next)04-29
Inst Owners100.96%
Inst Owner Change0.1%
Ins Owners0.37%
Ins Owner Change3.9%
Market Cap10.40B
Revenue(TTM)3.22B
Net Income(TTM)348.90M
Analysts82.58
Price Target91.69 (69.48%)
Short Float %4.61%
Short Ratio4.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-139.93%
Min EPS beat(2)-142.18%
Max EPS beat(2)-137.68%
EPS beat(4)2
Avg EPS beat(4)-50.99%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)-11.67%
EPS beat(12)8
Avg EPS beat(12)-5.02%
EPS beat(16)11
Avg EPS beat(16)-18.07%
Revenue beat(2)1
Avg Revenue beat(2)0.52%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)3.57%
Revenue beat(4)2
Avg Revenue beat(4)1.54%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)5
Avg Revenue beat(8)2.04%
Revenue beat(12)6
Avg Revenue beat(12)0.83%
Revenue beat(16)8
Avg Revenue beat(16)0.27%
PT rev (1m)-0.87%
PT rev (3m)-0.42%
EPS NQ rev (1m)-11.27%
EPS NQ rev (3m)-27%
EPS NY rev (1m)-6.52%
EPS NY rev (3m)-2.96%
Revenue NQ rev (1m)-1.16%
Revenue NQ rev (3m)-6.71%
Revenue NY rev (1m)1.48%
Revenue NY rev (3m)5.02%
Valuation
Industry RankSector Rank
PE 30.39
Fwd PE 12.37
P/S 3.23
P/FCF 14.51
P/OCF 12.57
P/B 1.71
P/tB 1.83
EV/EBITDA 9.66
EPS(TTM)1.78
EY3.29%
EPS(NY)4.37
Fwd EY8.08%
FCF(TTM)3.73
FCFY6.89%
OCF(TTM)4.31
OCFY7.96%
SpS16.75
BVpS31.65
TBVpS29.52
PEG (NY)0.21
PEG (5Y)N/A
Graham Number35.6033 (-34.19%)
Profitability
Industry RankSector Rank
ROA 4.59%
ROE 5.73%
ROCE 12.75%
ROIC 9.64%
ROICexc 12.49%
ROICexgc 13.54%
OM 27.06%
PM (TTM) 10.83%
GM 81.43%
FCFM 22.26%
ROA(3y)4.38%
ROA(5y)2.86%
ROE(3y)5.55%
ROE(5y)3.65%
ROIC(3y)6.29%
ROIC(5y)N/A
ROICexc(3y)7.4%
ROICexc(5y)N/A
ROICexgc(3y)8.13%
ROICexgc(5y)N/A
ROCE(3y)8.32%
ROCE(5y)N/A
ROICexgc growth 3Y117.77%
ROICexgc growth 5YN/A
ROICexc growth 3Y120.08%
ROICexc growth 5YN/A
OM growth 3Y106.3%
OM growth 5YN/A
PM growth 3Y17.04%
PM growth 5Y-25.17%
GM growth 3Y1.91%
GM growth 5Y2.54%
F-Score6
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.83
Debt/EBITDA 0.63
Cap/Depr 139.49%
Cap/Sales 3.45%
Interest Coverage 120.32
Cash Conversion 87.04%
Profit Quality 205.51%
Current Ratio 5.21
Quick Ratio 3.5
Altman-Z 5.48
F-Score6
WACC8.91%
ROIC/WACC1.08
Cap/Depr(3y)114.54%
Cap/Depr(5y)116.58%
Cap/Sales(3y)3.77%
Cap/Sales(5y)4.81%
Profit Quality(3y)115.9%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.46%
EPS 3Y83.09%
EPS 5Y-17.11%
EPS Q2Q%-137.5%
EPS Next Y145.65%
EPS Next 2Y80.04%
EPS Next 3Y59.23%
EPS Next 5Y41.22%
Revenue 1Y (TTM)12.87%
Revenue growth 3Y15.4%
Revenue growth 5Y11.6%
Sales Q2Q%17.03%
Revenue Next Year14.32%
Revenue Next 2Y13.27%
Revenue Next 3Y11.87%
Revenue Next 5Y11.79%
EBIT growth 1Y53.85%
EBIT growth 3Y138.08%
EBIT growth 5YN/A
EBIT Next Year44.86%
EBIT Next 3Y33.16%
EBIT Next 5Y24.75%
FCF growth 1Y50.82%
FCF growth 3Y152.76%
FCF growth 5YN/A
OCF growth 1Y44.54%
OCF growth 3Y67.59%
OCF growth 5Y57.51%

BIOMARIN PHARMACEUTICAL INC / BMRN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?

ChartMill assigns a fundamental rating of 7 / 10 to BMRN.


What is the valuation status for BMRN stock?

ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.


What is the profitability of BMRN stock?

BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 8 / 10.


What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?

The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 145.65% in the next year.